Sunday, September 6, 2026 See who Washington just made rich Get the free brief →
Money Racket
Who Cashes In When Washington Moves
HEALTHCARE & FDAFDA Approves Camizestrant for ESR1+ Breast CanceryesterdayHEALTHCARE & FDAFDA Approves Tudriqev for Advanced Melanoma4 weeks agoHEALTHCARE & FDAFDA Acts to Prevent Neonatal Nutrition Supply ShortageyesterdayTRADE & TARIFFSRetailers Sell Off Tariff Refund Rights for Cash—Windfall Monetized Before Payout4 weeks agoHEALTHCARE & FDAFDA Seeks Input on Botanical Drug PathwaysyesterdayTECHU.S. Signs $874M Semiconductor Research LOIs—Chip Makers Get Federal Backing4 weeks agoHEALTHCARE & FDAFDA Authorizes Screwworm Prevention for PetsyesterdayWHITE HOUSEDHS Tightens H-1B/L-1 Visa Fees—Tech Hiring Costs Rise for Employers4 weeks agoMARKETSCFTC Clears CAD and MXN Swap TransitionsyesterdayENERGYMichigan Court Rejects Enbridge Line 5 Permit Under Great Lakes4 weeks agoENERGYEPA Extends RFS Reporting Deadline One Month2 days agoDEFENSEPentagon Awards Space-Based Target Tracking Contracts4 weeks agoHEALTHCARE & FDAFDA Approves First Alexander Disease Drug2 days agoTECHTrump Administration Adds 6 Chipmakers to U.S. Portfolio4 weeks agoWHITE HOUSEFinCEN Tightens Southwest Border Money Reporting2 days agoWHITE HOUSEWhite House Drafts Vaccine-Autism Order—Pharma Faces Uncertainty4 weeks agoDEFENSEPratt & Whitney Engine Flaw Drives MRO Workload3 days agoDEFENSETrump Pushes $1.5T Defense Budget—Lockheed, RTX, GD Lock in Gains4 weeks agoDEFENSEAirbus Landing Gear Flaw Expands MRO Workload3 days agoWHITE HOUSETrump Order Splits MMR Vaccine—Pharma Faces Demand Shift4 weeks agoTECHDHS Awards AWS $60M Cloud Hosting Deal3 days agoWHITE HOUSETrump Orders Childhood Vaccine Schedule Spacing4 weeks agoWHITE HOUSEGardaWorld Wins $100M ICE Armed Transport Deal3 days agoHEALTHCARE & FDAFDA Updates Fresh-Cut Produce Safety Guidance4 weeks agoENERGYNASA Awards Sierra Lobo $77M for Space Reactor3 days agoENERGYNRC Approves NAC MAGNASTOR Spent Fuel Storage Cask4 weeks agoTECHAccenture Wins $30M DOE Modernization Contract4 days agoHEALTHCARE & FDAFDA Clears Screwworm Prevention Drug for U.S. Livestock4 weeks agoDEFENSETrump Scales Back Korea Exercises—Defense Contractors Face Uncertainty4 days agoDEFENSEIonQ Lands $28M U.S. Defense Quantum Contract3 weeks agoWHITE HOUSETrump Bans Foreign Grid Equipment—US Suppliers Win4 days agoTECHFCC Eases Broadband Label Rules—ISPs Win Flexibility3 weeks agoENERGYDOE Stays Clean Energy Building Rules—Fossil Fuel Lobby Wins Reprieve4 days agoDEFENSEBlackSky Lands Multi-Year Satellite Contract3 weeks agoHEALTHCARE & FDAFDA Approves Lisraya for Dermatomyositis—Rare-Disease Win5 days agoHEALTHCARE & FDASimparica Trio Gets Screwworm EUA—Zoetis Wins3 weeks agoMARKETSFDIC Eases Reciprocal Deposit Rules—Bank Funding Win5 days agoTRADE & TARIFFSTrump Tariffs on Drones Boost U.S. Makers3 weeks agoMARKETSFTC Sues Amazon Over Ad Auction Manipulation—Antitrust5 days agoTRADE & TARIFFSKimberly-Clark Pockets $45M Tariff Refund3 weeks agoENERGYTrump Admin Fast-Tracks Alaska Oil Pipeline—Energy Win5 days agoCRYPTOSEC Delays Crypto Rules—Uncertainty Persists3 weeks agoCRYPTOSEC Proposes Tailored Crypto Offering Rules—Clarity Win5 days agoTRADE & TARIFFSTariff Refunds Turbocharge Retailer Earnings3 weeks agoDEFENSEBoeing Wins $131B F-15 Contract—Fighter Jet Dominance6 days agoENERGYArmy Corps Permits Line 5 Tunnel—Michigan Blocks Path3 weeks agoCRYPTOSEC Proposes Crypto Offering Exemptions—Regulatory Clarity6 days agoTRADE & TARIFFSTariff Refunds Flow to Retailers—Earnings Boost3 weeks agoENERGYCentrus HALEU Enrichment Wins Policy Tailwind—Nuclear Fuel6 days agoHEALTHCARE & FDACMS Ends Medicare Part D Subsidy—Insurers Face Pressure3 weeks agoHEALTHCARE & FDAWhat Is a PDUFA Date?6 days agoWHITE HOUSETrump Vaccine Spacing Order Reshapes Pharma Demand3 weeks agoMARKETSWhat Is a Negotiated Price6 days agoENERGYEPA Exempts Calcium Carbonate From Pesticide Tolerance—Farm Input Eases3 weeks agoHEALTHCARE & FDAFDA Approves Mimrylo for Polycythemia Veralast weekDEFENSETrump's $1.5T Defense Push Fuels Colorado Contractor Windfall3 weeks agoHEALTHCARE & FDAFDA Authorizes Generic Bimectin for Screwworm Preventionlast weekHEALTHCARE & FDAFTC Probes Epic Systems Over Health Records Monopoly3 weeks agoHEALTHCARE & FDAFDA Opens GenAI Medical Device Regulation to Public Inputlast weekHEALTHCARE & FDAFDA Reclassifies Cancer Tests—Easier Path for Diagnostics3 weeks agoHEALTHCARE & FDATrump Admin Blocks $1.6B in Fraudulent Medicare Lab Paymentslast weekTECHCommerce Eases Drone Export Rules—U.S. Makers Win3 weeks agoTECHNHTSA Extends Comment Period on Vehicle Safety Exemptionslast weekDEFENSERTX Lands Fresh Missile Defense Contract—Stock Undervalued3 weeks agoENERGYBLM Launches 30-Year Permit for Trans-Alaska Pipeline Operationslast weekENERGYNewsom Passes Diablo Canyon Decision to Successor2 weeks agoMARKETSFTC Blocks Henkel's $725M Liquid Nails Bid—Antitrust Winslast weekHEALTHCARE & FDAGAO Finds $7.6B Medicare Hospice Overpayment2 weeks agoHEALTHCARE & FDAFDA Approves First RAS Inhibitor for Pancreatic Cancerlast weekWHITE HOUSEFinCEN Finalizes BOI Exemption for U.S. Persons2 weeks agoDEFENSEBoeing Lands $131B F-15 Contract—Fighter Jet Dominancelast weekENERGYFederal Court Orders Enbridge Line 5 Removal2 weeks agoHEALTHCARE & FDACostco Enters Medicare Advantage—Retail Disruption Loomslast weekENERGYEnbridge Wins Federal Permit for Line 5 Tunnel2 weeks agoTRADE & TARIFFSTrump's 50% Canada Tariffs Take Effect—Retailers Bracelast weekTECHD-Wave Wins Canadian Quantum Funding for Annealing2 weeks agoTRADE & TARIFFSU.S. Rolls Out Iran Sanctions—Oil Prices Sliplast weekHEALTHCARE & FDATrump Vaccine Spacing Order Reshapes Pharma Demand2 weeks agoHEALTHCARE & FDAAbbott's Dual Glucose-Ketone Monitor Wins FDA Nodlast weekTRADE & TARIFFSTariff Refunds Turbocharge Retailer Earnings2 weeks agoHEALTHCARE & FDARegeneron's Gene Therapy Wins First GSD Type Ia Approvallast weekDEFENSEFAA Engine Inspection Order Lifts MRO Stocks2 weeks agoDEFENSEStryker Lands $100M Defense Contract—Combat Vehicle Boostlast weekTECHUtah Governor Signs Quantum Computing Initiative Orderlast weekTRADE & TARIFFSWalmart Deploys $2.9B Tariff Refund Into Price Cutslast weekTRADE & TARIFFSTrump Administration Targets Iran's Banking System With New Sanctionslast weekTRADE & TARIFFSTrump Lifts Ground Beef Tariffs—Ranchers Face Price Pressurelast weekTECHCHIPS Act Transforms Binghamton Into Semiconductor Hublast weekWHITE HOUSETrump Kills Affirmative Action Rules—Contractors Face Compliance Shiftlast weekWHITE HOUSELabor Dept Eases Veteran Hiring Rules—Contractors Cut Compliancelast weekHEALTHCARE & FDAFDA Clears Robotic Blood Draw—Phlebotomy Shortage Easeslast weekWHITE HOUSELabor Dept Eases Disability Hiring Rules—Contractors Save Compliance Costslast week
Healthcare & FDA

FDA Approves Camizestrant for ESR1+ Breast Cancer

Eli Lilly and Pfizer's CDK4/6 partners see demand lift for resistant tumors.

Image: Money Racket
By at Money Racket · Sep 5, 2026
1-YEAR MOVE
+22% −15%
LLY ▲11.9% PFE ▲10.1%
1-year price move by ticker
TickerCompany1-year change
LLYEli Lilly+11.9%
PFEPfizer+10.1%

The FDA granted accelerated approval to Etcamah (camizestrant) on September 4, 2026, for advanced breast cancer patients with ESR1 mutations who have progressed on aromatase inhibitors and CDK4/6 inhibitors. ESR1 mutations are acquired resistance mutations that emerge during endocrine therapy, affecting a subset of HR-positive, HER2-negative patients.

Free alerts

Free: catalyst alerts, straight to your inbox.

Get the White House orders, federal contracts, and FDA decisions that move money — with who cashes in — free. Unsubscribe in one click.

Free · weekly · unsubscribe anytime. Privacy.

Camizestrant is approved only in combination with Lilly and Pfizer's CDK4/6 inhibitors, so both companies cash in on a new indication that extends their franchise.

The direct winners are the CDK4/6 inhibitor makers: Eli Lilly LLY and Pfizer PFE both profit because camizestrant is approved only in combination with their existing drugs—abemaciclib (Lilly), palbociclib (Pfizer), or ribociclib (Roche, private). Lilly and Pfizer now have a new indication that extends the life cycle of their franchise and justifies higher combination pricing. The approval also benefits Seagen (SGEN), which is owned by Pfizer and develops oncology therapies; any expansion of the breast-cancer treatment armory lifts the entire franchise.

No clear loser here—this is a narrow, late-line indication that fills an unmet need rather than displacing existing therapies. Patients who fail first-line CDK4/6 therapy now have a path forward instead of moving to chemotherapy, which actually protects the CDK4/6 market from erosion.

Watch for real-world adoption data in Q4 2026 and early 2027. If ESR1 testing becomes standard at progression, the addressable population expands and drives higher combination volumes.

Source: original report ↗

Knowing who cashed in is only half the trade.

Every catalyst has a second move — the supplier, the sector, the part already priced in. Money Racket Pro hands you that read on every policy event, plus the pre-market brief six mornings a week, before the open.

Get the edge · $40/mo

Join the readers who get there before the financial press. Cancel anytime, one click.

Share

https://moneyracket.com/article/fda-approves-camizestrant-breast-cancer-esr1/

Discussion

    Leave a comment

    Comments are reviewed before they appear.
    Money Racket Pro

    By the time it's news, the money's already moved.

    The contract award, the executive order, the tariff cut — it mints winners before the financial press connects the dots. Pro gets you there first: what happened, who cashes in, and exactly what to watch — in a two-minute read.

    Get the free brief The policy-to-profit brief. Cancel anytime.
    The pre-market brief · Mon–Sat, 7:45am ET Get the free brief →